NCT05627245 2026-03-18
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
National Cancer Institute (NCI)
Centre Oscar Lambret
Mayo Clinic
Stanford University
M.D. Anderson Cancer Center